MANUEL CALVIN: Open Payments
NPI 1396744678 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,430 in 135 payments from 10 companies in 2025. Trend: 2023 $3,444 · 2024 $3,494 · 2025 $2,430
Food & beverage: $2,430
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $785 |
| Amgen Inc. | 47 | $633 |
| PFIZER INC. | 14 | $320 |
| Novartis Pharmaceuticals Corporation | 10 | $215 |
| UCB, Inc. | 7 | $151 |
| GlaxoSmithKline, LLC. | 7 | $137 |
| AstraZeneca Pharmaceuticals LP | 5 | $87 |
| E.R. Squibb & Sons, L.L.C. | 2 | $51 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Genentech USA, Inc. | 1 | $15 |
Products named: RINVOQ, ENBREL, XELJANZ, SKYRIZI, COSENTYX, Bimzelx, BENLYSTA, TAVNEOS.
Industry payments across OK — which companies pay providers there.
